Nicole Wyman Engen
#3,776,460
Most Influential Person
Researcher
Why Is Nicole Wyman Engen Influential?
(Suggest an Edit or Addition)Nicole Wyman Engen's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Papers
- A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 (2020) (1047)
- Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 (2020) (236)
- Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial (2019) (80)
- Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial (2019) (80)
- Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial (2021) (79)
- Improved quality of life with immediate versus deferred initiation of antiretroviral therapy in early asymptomatic HIV infection (2017) (75)
- Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial (2020) (73)
- Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial (2020) (62)
- Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19 (2020) (37)
- Symptoms of COVID-19 Outpatients in the United States (2020) (37)
- Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial (2017) (36)
- INSIGHT FLU005: An Anti-Influenza Virus Hyperimmune Intravenous Immunoglobulin Pilot Study. (2016) (20)
- Early Antiretroviral Therapy at High CD4 Counts Does Not Improve Arterial Elasticity: A Substudy of the Strategic Timing of AntiRetroviral Treatment (START) Trial (2016) (19)
- Phase I EnACT Trial of the Safety and Tolerability of a Novel Oral Formulation of Amphotericin B (2020) (18)
- Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19 (2020) (17)
- Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial (2022) (15)
- Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial (2020) (15)
- A randomized evaluation of on-site monitoring nested in a multinational randomized trial (2020) (14)
- Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009–2015 (2017) (13)
- Investigating the Efficacy of Clinical Trial Monitoring Strategies (2015) (13)
- Assessment of arterial elasticity among HIV‐positive participants with high CD4 cell counts: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial (2015) (11)
- Increased Indoleamine-2,3-Dioxygenase Activity Is Associated With Poor Clinical Outcome in Adults Hospitalized With Influenza in the INSIGHT FLU003Plus Study (2017) (11)
- Inflammation Associates With Impaired Small Arterial Elasticity Early in HIV Disease (2018) (8)
- The rate of bone loss slows after 1–2 years of initial antiretroviral therapy: final results of the Strategic Timing of Antiretroviral Therapy (START) bone mineral density substudy (2020) (5)
- Lessons Learned From Conducting Internet-Based Randomized Clinical Trials During a Global Pandemic (2020) (3)
- Therapeutic Lumbar Punctures in Human Immunodeficiency Virus–Associated Cryptococcal Meningitis: Should Opening Pressure Direct Management? (2022) (1)
- Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: Study Protocol for a Pragmatic Randomized Controlled Trial (2020) (1)
- Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 (2022) (0)
- 1716. Baseline Serum C-Reactive Protein Level Predicts Mortality in Cryptococcal Meningitis (2019) (0)
- Safety and tolerability of a novel oral formulation of amphotericin B: Phase I EnACT Trial 1 (2020) (0)
- Feasibility of SARS-CoV-2 Antibody Testing in Remote Outpatient Trials (2021) (0)
- Baseline Serum C-Reactive Protein Level Predicts Mortality in Cryptococcal Meningitis (2019) (0)
- Recurrence of symptoms following cryptococcal meningitis - characterizing a diagnostic conundrum with multiple etiologies. (2022) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Nicole Wyman Engen?
Nicole Wyman Engen is affiliated with the following schools:
